Patrick J. McEnany - 15 May 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role: President and CEO, Director
Signature: /s/ Patrick J. McEnany
Issuer symbol: CPRX
Transactions as of: 15 May 2023
Net transactions value: -$187,978
Form type: 4
Filing time: 17 May 2023, 17:04:23 UTC
Previous filing: 17 Feb 2023
Next filing: 12 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CPRX	Common stock, par value $0.001 per share	Options Exercise	$20,659	+26,151	+0.66%	$0.7900^*	3,971,587	15 May 2023	Direct
transaction	CPRX	Common stock, par value $0.001 per share	Sale	$345,978	-26,151	-0.66%	$13.23	3,945,436	15 May 2023	Direct	F1, F2
transaction	CPRX	Common stock, par value $0.001 per share	Options Exercise	$137,341	+173,849	+4.4%	$0.7900^*	4,119,285	16 May 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CPRX	Options to purchase common stock	Options Exercise	$0	-26,151	-0.84%	$0.000000	3,101,516	15 May 2023	Common Stock	26,151	$0.7900	Direct	F3
transaction	CPRX	Options to purchase common stock	Options Exercise	$0	-173,849	-5.6%	$0.000000	2,927,667	16 May 2023	Common Stock	173,849	$0.7900	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were sold to cover tax withholding requirements.
F2	Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.20 to $13.285 per share.
F3	Options vested in two equal tranches beginning on June 15, 2017.